Apogee Therapeutics Inc. (APGE)
(Delayed Data from NSDQ)
$45.64 USD
-0.72 (-1.55%)
Updated May 31, 2024 04:00 PM ET
After-Market: $45.72 +0.08 (0.18%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
APGE 45.64 -0.72(-1.55%)
Will APGE be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for APGE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APGE
Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why
APGE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for APGE
Buy Rating for Apogee Therapeutics: Promising Prospects for Dupixent and APG808 in COPD Market
Apogee Therapeutics Welcomes Dr. Bollinger to Board
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
Apogee Therapeutics expands board of directors with appointment of Bollinger
Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo